OnKure Therapeutics (OKUR) Change in Accured Expenses (2020 - 2026)

OnKure Therapeutics (OKUR) has 7 years of Change in Accured Expenses data on file, last reported at -$905000.0 in Q1 2026.

• Quarterly Change in Accured Expenses rose 46.07% year-over-year to -$905000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$3.8 million (up 35.71% YoY) and the FY2025 annual result came in at -$4.5 million, up 23.32% from the prior year.
• Change in Accured Expenses slipped to -$905000.0 in Q1 2026, from -$305000.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $7.5 million in Q2 2024 to a low of -$11.1 million in Q4 2024.
• A 5-year average of -$538000.0 and a median of -$567000.0 in 2024 frame the typical range for Change in Accured Expenses.
• The widest YoY moves for Change in Accured Expenses: up 62650.0% in 2022, down 3462.32% in 2022.
• Tracing OKUR's Change in Accured Expenses over 5 years: stood at -$2.3 million in 2022, then plunged by 106.64% to -$4.8 million in 2023, then tumbled by 131.08% to -$11.1 million in 2024, then jumped by 97.25% to -$305000.0 in 2025, then tumbled by 196.72% to -$905000.0 in 2026.
• The last three Change in Accured Expenses figures came in at -$905000.0 (Q1 2026), -$305000.0 (Q4 2025), and -$1.4 million (Q3 2025), per Business Quant data.